<DOC>
	<DOCNO>NCT01846975</DOCNO>
	<brief_summary>RA ( rheumatoid arthritis ) patient effectively treat weekly SC ( subcutaneous ) Abatacept switch IV ( intravenous ) Abatacept restart SC Abatacept four IV application . The investigator hypothesize switch SC- IV-abatacept back patient low disease activity safe associate worsen disease .</brief_summary>
	<brief_title>Introducing Single IV Abatacept Treatment RA Patients Currently Receiving Weekly SC Abatacept Simulate Holiday</brief_title>
	<detailed_description>Abatacept recombinant fusion protein compose Fc region Immunoglobulin IgG1 fuse extracellular domain human cytotoxic T-Lymphocyte Antigen 4 ( CTLA-4 ) modify prevent antibody-dependent cellular cytotoxicity complement fixation . Abatacept selective co-simulation modulator inhibit co-stimulation T-cells . Abatacept currently approve use rheumatoid arthritis ( RA ) useful symptom reduction delay progression structural damage . RA chronic inflammatory autoimmune disease . With introduction biological disease-modifying antirheumatic drug ( DMARDs ) ( biologics ) , option treatment RA dramatically change . Abatacept currently biologic available , subcutaneous ( SC ) intravenous ( IV ) formulation . The efficacy safety profile IV-Abatacept well establish last year clinical trial compare SC-Abatacept IV-Abatacept clearly demonstrate equal efficacy safety profile . Importantly , switch IV- SC-Abatacept appear associated persist good efficacy Abatacept increase adverse event ( AE ) . On hand , however , switch SC- IV-Abatacept subject clinical trial . This Phase IV study aim review transition weekly SC- single IV-Abatacept also return weekly SC treatment 4 week break . Holiday season present major problem RA patient treat weekly subcutaneous biologics , include SC-Abatacept . Therefore evaluation use IV-Abatacept treatment cover 4 week break may present acceptable treatment alternative patient population .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>1 . Male female subject age 18 year old time consent 2 . Able give inform consent 3 . Patients classify RA accord 2010 American College Rheumatology/European League Rheumatism ( ACR/EULAR ) criterion ( Aletaha D et al , 2010 ) 4 . Patient treat weekly SCAbatacept least 3 month prior study screen 5 . Effective control disease activity define DAS28 ( ESR ) &lt; 3.2 ( LDAS ) 6 . Available whole duration study 7 . Female subject childbearing potential must use maximally effective birth control period therapy , must willing use contraception duration study ( 168 day post IV infusion Abatacept ) . They also must negative pregnancy test upon entry study . Otherwise , female subject must postmenopausal ( menstrual period minimum 12 month ) surgically sterile . 8 . Male subject must surgically sterile willing use double barrier contraception method upon enrolment , duration study ( 168 day post IV infusion Abatacept ) 1 . Subjects previously receive &gt; 2 biologic DMARDs 2 . Pregnant breastfeed woman childbearing potential unwilling unable use acceptable method contraception avoid pregnancy entire study period ( Day 168/Safety followup visit ) 3 . Subjects active vasculitis major organ system , exception rheumatoid nodules 4 . Subjects current symptom severe , progressive , uncontrolled renal , hepatic , hematologic , gastrointestinal , pulmonary , cardiac , neurologic , cerebral disease , whether related RA , opinion investigator , might place subject unacceptable risk participation study 5 . Subjects history cancer last 5 year , current screen suspicious cancer , nonmelanoma skin cell cancer cure local resection carcinoma situ 6 . Subjects evidence active latent bacterial ( e.g . tuberculosis ) viral infection ( e.g . Human Immunodeficiency Virus ( HIV ) time potential enrolment 7 . Subjects herpes zoster cytomegalovirus ( CMV ) resolve less 2 month inform consent document sign 8 . Subjects receive live vaccine within 3 month anticipate first dose study medication 9 . Having participate another drug interventional study within 30 day precede present study screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Abatacept</keyword>
	<keyword>Low disease activity</keyword>
	<keyword>Intravenous</keyword>
	<keyword>Subcutaneous</keyword>
	<keyword>Rheumatoid arthritis</keyword>
</DOC>